Roche extends offer for Spark until Nov. 25

Roche said it extended its tender offer for shares of Spark Therapeutics, Inc. until Nov. 25 to give the U.S. Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) more time to complete their reviews of the $4.3 billion deal.